Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. Therasse P, et al. Among authors: wanders j. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. doi: 10.1093/jnci/92.3.205. J Natl Cancer Inst. 2000. PMID: 10655437
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
Schellens JH, Heinrich B, Lehnert M, Gore ME, Kaye SB, Dombernowsky P, Paridaens R, van Oosterom AT, Verweij J, Loos WJ, Calvert H, Pavlidis N, Cortes-Funes H, Wanders J, Roelvink M, Sessa C, Selinger K, Wissel PS, Gamucci T, Hanauske AR. Schellens JH, et al. Among authors: wanders j. Invest New Drugs. 2002 Feb;20(1):83-93. doi: 10.1023/a:1014454821885. Invest New Drugs. 2002. PMID: 12003197 Clinical Trial.
Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
Eskens FA, Greim GA, van Zuylen C, Wolff I, Denis LJ, Planting AS, Muskiet FA, Wanders J, Barbet NC, Choi L, Capdeville R, Verweij J, Hanauske AR, Bruntsch U. Eskens FA, et al. Among authors: wanders j. Clin Cancer Res. 2000 May;6(5):1736-43. Clin Cancer Res. 2000. PMID: 10815892 Clinical Trial.
Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.
Awada A, Eskens FA, Piccart M, Cutler DL, van der Gaast A, Bleiberg H, Wanders J, Faber MN, Statkevich P, Fumoleau P, Verweij J; EORTC Early Clinical Studies Group. Awada A, et al. Among authors: wanders j. Eur J Cancer. 2002 Nov;38(17):2272-8. doi: 10.1016/s0959-8049(02)00379-9. Eur J Cancer. 2002. PMID: 12441264 Clinical Trial.
109 results